Effect of buyang huanwu decoction combined with bone marrow mesenchymal stem cell transplantation on cerebral ischemia-reperfusion injury

doi:10.3969/j.issn.2095-4344.2015.50.015

Abstract

Abstract:

BACKGROUND: When acute cerebral ischemia attacks, matrix metalloproteinases (MMPs) lead to the occurrence of cerebral edema through degrading the extracellular matrix, breaking the close connection between endothelial cells, increasing the permeability of capillaries, and destroying the blood brain barrier.
OBJECTIVE: From the aspects of MMPs and extracellular matrix, to discuss the therapeutic effects of buyang huanwu decoction combined with bone marrow mesenchymal stem cell (BMSCs) transplantation on cerebral ischemia-reperfusion injury.

METHODS: A total of 96 Sprague-Dawley rats were randomly divided into model group, tissue inhibitor of MMPs-1 (TIMP-1) group, TIMP-1+BMSCs group (BMSCs group) and buyang huanwu decoction+BMSCs+TIMP-1 group (combined group that was divided into four subgroups, 12-, 24-, 36-, 48-hour groups). Rat models of cerebral ischemia-reperfusion were constructed, and TIMP-1 and BMSCs were injected to the brain of rats by a microinjector in a stereotaxic apparatus. Rats in the combined group were given buyang huanwu decoction (10 mL/kg), and rats in the other groups were given the same volume of normal saline at 7 days before surgery. After 10 days of administration, serum samples and brain tissues were collected to determine MMP-2 and MMP-9 levels using ELISA and to detect MMP-9 activity using gelatinases spectrometry method.
RESULTS AND CONCLUSION: Compared with the model group, the levels of MMP-2 and MMP-9 in the serum and MMP-9 activity in the brain were decreased in the other groups to different extents, especially the levels of MMP-9 (P < 0.05). Compared with the BMSCs group, the levels of MMP-2 and MMP-9 in serum as well as activities of MMP-9 and pro-MMP-9 in the brain were decreased significantly in the combined group at 36 and 48 hours after treatment (P < 0.01). The results show that the buyang huanwu decoction can be mutually cooperated with TIMP-1 to inhibit the degradation of extracellular matrix induced by MMP-2 and MMP- 9, repair the damaged blood brain barrier, prevent and cure cerebral edema after ischemia.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

CLC Number:

R394.2

Zhang Yun-ke, Song Jun-ying, Zhang Zhen-qiang. Effect of buyang huanwu decoction combined with bone marrow mesenchymal stem cell transplantation on cerebral ischemia-reperfusion injury[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(50): 8120-8125.

Figures/Tables 2

References

[1] MacGregor DG, Avshalumov MV, Rice ME. Brain edema induced by in vitro ischemia: causal factors and neuroprotection. J Neurochem. 2003;85(6):1402-1411.

[2] Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011; 11(5):352-363.

[3] Day RE, Kitchen P, Owen DS, et al. Human aquaporins: regulators of transcellular water flow. Biochim Biophys Acta. 2014;1840(5):1492-1506.

[4] Newman KM, Jean-Claude J, Li H, et al. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg. 1994;20(5):814-820.

[5] 张运克.补阳还五汤及拆方对脑缺血再灌注SD大鼠模型脑组织含水量及Ca2+含量的影响[J].中医药学刊,2003,21(11):1829-1830.

[6] 高颖,蔡定芳.AO大鼠MMP-9蛋白表达及补阳还五汤干预作用[J].复旦学报:医学版,2003,30(5):470-473.

[7] Zhang YK, Han XY, Che ZY. Effects of buyang huanwu tang combined with bone marrow mesenchymal stem cell transplantation on the expression of VEGF and Ki-67 in the brain tissue of the cerebral ischemia-reperfusion model rat. J Tradit Chin Med. 2010;30(4):278-282.

[8] 张运克,高峰,张丹,等.补阳还五汤联合骨髓间充质干细胞移植对脑缺血再灌注大鼠脑组织NSE和GFAP表达的影响[J].中医杂志,2013,54(23):2043-2045.

[9] 张运克,车志英,梅雪蕊. 补阳还五汤联合骨髓间充质干细胞移植对大鼠脑缺血再灌注模型神经细胞凋亡的影响[J].中华中医药学刊,2009,27(8):1660-1662.

[10] 张运克,车志英,梅雪蕊.补阳还五汤联合骨髓间充质干细胞移植对脑缺血再灌注大鼠行为学及脑梗死体积的影响[J].辽宁中医杂志,2010,37(2):366-368.

[11] 郭继强,刘爱兵,王东平,等.密度梯度离心法分离脐血干细胞:分离介质的筛选[J].中国组织工程研究,2013,17(23):4189-4195.

[12] Rupadevi M, Parasuraman S, Raveendran R. Protocol for middle cerebral artery occlusion by an intraluminal suture method. J Pharmacol Pharmacother. 20112(1):36-39.

[13] Legos JJ, Barone FC. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs. 2003;4(7):847-858.

[14] 魏汝云,徐婧婧,王淑贞.基质金属蛋白酶-9与脑缺血损伤的关系研究进展[J].中国现代医学杂志,2007,17(5):565-568.

[15] Hulkkonen J, Pertovaara M, Antonen J, et al. Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome. Rheumatology (Oxford). 2004;43(12):1476-1479.

[16] Wu CY, Hsieh HL, Jou MJ, et al. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J Neurochem. 2004;90(6): 1477-1488.

[17] Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003; 253(1-2):269-285.

[18] Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol. 1996;55(12):1194-1204.

[19] Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol. 1996; 55(3):300-309.

[20] Rosenberg GA, Navratil M, Barone F, et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16(3):360-366.

[21] Mandal M, Mandal A, Das S, et al. Clinical implications of matrix metalloproteinases. Mol Cell Biochem. 2003;252(1-2): 305-329.

[22] Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. 2011;20(1): 47-54.

[23] Vlodavsky E, Palzur E, Soustiel JF. Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury. Neuropathol Appl Neurobiol. 2006;32(1):40-50.

[24] Reyes R, Guo M, Swann K, et al. Role of tumor necrosis factor-alpha and matrix metalloproteinase-9 in blood-brain barrier disruption after peripheral thermal injury in rats. J Neurosurg. 2009;110(6):1218-1226.

[25] Fujimoto M, Takagi Y, Aoki T, et al. Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab. 2008; 28(10):1674-1685.

[26] Zhang Y, Zhang P, Shen X, et al. Early exercise protects the blood-brain barrier from ischemic brain injury via the regulation of MMP-9 and occludin in rats. Int J Mol Sci. 2013;14(6):11096-11112.

[27] 吴飞燕,罗利飞.补阳还五汤对急性脑梗死患者血浆超敏C反应蛋白及基质金属蛋白-9的影响[J].中国中医急症,2011,20(1): 14-15,32.

[28] 王红祥,徐彬,万海同.黄芪对脑缺血-再灌注损伤大鼠MMP-9和IL-1β的影响[J].海峡药学,2013,25(4):17-19.

[29] 李敬文,刘相轸,刘晓谦,等.川芎嗪对颈动脉球囊损伤后基质金属蛋白酶组织抑制物-1基因表达的影响[J].中国微侵袭神经外科杂志,2004,9(7):314-317.

[30] 王栋,赵恒珂,孙银贵,等.红花注射液后处理对大鼠缺血再灌注心肌的保护作用探讨[J].临床合理用药杂志,2011,4(13):24-26.

[31] 方顺淼,张清华.髓间充质干细胞移植修复动脉粥样硬化破裂斑块的研究[J].中华老年心脑血管病杂志,2012,14(11):1197-1200.